SELLAS Life Sciences Group, Inc. SLS

SLS Company Overview

SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of cancer immunotherapies and hematology-oncology therapeutics. The company operates primarily in the biotechnology and oncology drug development industries, with an emphasis on therapies targeting difficult-to-treat cancers and hematologic malignancies. SELLAS is publicly traded on Nasdaq under the ticker SLS and has concentrated its efforts on advancing clinical-stage assets through regulatory development and strategic partnerships.

The company’s primary value drivers are its lead product candidates, including galinpepimut-S (GPS), a Wilms Tumor 1 (WT1)-targeting cancer immunotherapy, and SLS009 (tambiciclib), a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor under development for hematologic cancers. SELLAS has historically focused on leveraging immunotherapeutic approaches alongside precision oncology strategies for patients with limited treatment options. Originally formed through a combination involving Galena Biopharma’s oncology assets and later restructured under the SELLAS brand, the company evolved into a clinical-stage oncology developer with a pipeline centered on immuno-oncology and targeted therapeutics.